Beacon Angels covered the following topics in its eleven regular meetings of 2021:

January 12, 2021

Did U Remember To & General Prognostics

Beacon Angels members heard the following new company presenters at its January meeting:

• Did U Remember To; which has develped a combined Bluetooth Low Energy Beacon and mobile app product for providing JIT reminders, notices and alerts to consumers and businesses throughout the world, and
• General Prognostics, which is developing a continuous blood biomarker monitoring platform to identify significant patient status changes, and to notify physician and patient, thus enabling therapy changes to avoid hospital readmissions.

We heard updates on the new funding rounds of:

• Cognoptix bridge debt;
• First Light Diagnostics, and
• RevBio (f/k/a Launchpad Medical).

February 9, 2021

ThoughtData & Everyday Life

Beacon Angels entertained the following new funding proposals at its February meeting:  

• ThoughtData, helping enterprise businesses to detect and resolve network, application and infrastructure performance issues more effectively with a better end-user experience, and
• Everyday Life, disrupting life insurance for everyday people.

Members reported on companies in due diligence consisting of General Prognostics.

We heard updates on the funding rounds of:

• Cognoptix bridge debt, and
• RevBio (f/k/a Launchpad Medical), and
• Lenoss Medical.

March 9, 2021

AOA Diagnostics & AIDX

Beacon heard the following new funding proposals at its March meeting:

• AOA Diagnostics developing a new and more accurate diagnostic method for ovarian cancer, and
• AIDX providing digital pooling worldwide, and initially in East Africa, whereby people can contribute regularly to a shared pot and agree upon the rules for how funds will be used.

April 13, 2021

Carmyn & Yarn Corporation

At its April meeting, Beacon Angels entertained the following new funding proposals:  

• Carmyn, offering a Gas Station on Wheels–saving shoppers time by refueling their cars in the store parking lot; and
• Yarn Corporation, developing Driftspace, the only “no code” app aimed at VR video content creators with a non-trival WYSIWYG editor and a real-time Web dashboard enabling copy and paste from email into headset content.

Members reported on companies in due diligence consisting of General Prognostics, Everyday Life and AOA Diagnostics.

We heard updates on the funding rounds of GelMEDIX and RevBio, plus an update on the new funding round of Xeno Biosciences delivered by CEO Dr. David Beno.

May 11, 2021

Octagon Therapeutics & Genomic Expressions

At its May meeting, Beacon Angels members entertained the following presenters:  

• Octagon Therapeutics, which is developing precision immunomodulators for chronic autoimmune diseasethat specifically target immune dysregulation; and
• Genomic Expressions, which offers OneRNA,® a disease agnostic exponentially scalable RNA analysis platform to detect disease, monitor health and design next-generation cures.

Members reported on companies in due diligence consisting of: 

• Yarn Corporation; and
• AOA Diagnostics.

We heard updates on the funding rounds of Cognoptix, GelMEDIX, RevBio and Xeno Biosciences.

June 8, 2021

TIKI, AmplifiDx & Hilltop BioSciences

At its June meeting, Beacon Angels members entertained funding proposals from the following presenters:

• TIKI, building software to accord ownership to social media users over the data collected on them consisting of seeing it, controlling how it is used, when it is sold, and how to get paid for its sale; and
• AmplifiDx, offering its Molecular Point-of-Care biotechnology platform in the development of the DX 1000 System for infectious disease testing at the point of care; and
• Hilltop BioSciences, a veterinary biotech offering novel therapies for inflammatory diseases such as equine asthma and canine osteoarthritis.

Members reported on Octagon Therapeutics in due diligence.

We heard updates on the funding rounds of AOA Dx, GelMEDIX; Cognoptix, RevBio, and Xeno Biosciences.

July 13, 2021

Intraday & Soul Being

At our meeting on July 13, 2021 the members of Beacon Angels entertained new funding proposals from the following presenters:

• Intraday, developing AI tools in the financial technology field to enable companies to forecast and deploy cash efficiently and more productively; and
• Soul Being, a healthcare services platform to help users navigate integrative medicine alternatives that improve their health while saving money for their employers and health plans.

CEO Adam Honig also delivered an update on Spiro Technologies.

Members reported on companies in due diligence consisting of: 

• AmplifiDx, offering a Molecular Point-of-Care biotechnology platform via the DX 1000 System for accurate, convenient, and affordable infectious disease testing;
• Hilltop BioSciences, a veterinary biotech company offering novel therapies for inflammatory diseases such as equine asthma and canine osteoarthritis; and
• TIKI, building software for users to own the data collected on them by social media companies consisting whereby they can see their data, control when and how it is sold and used, and get paid for its sale.

We heard updates on the funding rounds of:

• Cognoptix,RevBio, and
• Xeno Biosciences.

September 14, 2021

Phimentum, Reeske & Dermal Photonics

At its meeting on the morning of September 14, 2021, Beacon Angels members entertained funding proposals from:

• Phimentum, which supplies a novel form of therapeutic braces to general dentists, enabling them to generate high profits while lowering patient costs and geographic barriers; and
• Reeske, offering embeddable insurance technology for financial institutions to white-label life and disability insurance products to consumers, and
• Dermal Photonics, offering a patented device for home laser self-treatments superior to those of a professional dermatologist at a fraction of the cost.

Members reviewed due diligence reports on companies consisting of:

• AmplifiDx, offering a Molecular Point-of-Care biotechnology platform via the DX 1000 System for accurate, convenient, and affordable infectious disease testing;
• Hilltop BioSciences, a veterinary biotech offering novel therapies for inflammatory diseases such as equine asthma and canine osteoarthritis; and
• Intraday, developing AI tools in the financial technology field to enable companies to forecast and deploy cash efficiently and more productively.

Members heard an update on the upcoming funding round of AOA Dx, as well as portfolio company updates.

October 12, 2021

Embrace Prevention Care & NF2 Therapeutics

At its meeting on the morning of Tuesday, October 12, 2021, Beacon Angels members entertained new company funding proposals as follows:

• Embrace Prevention Care (speaking in person, David Dlesk, CEO), which provides Personal Prevention Care, an integrated suite of geriatric telehealth and pharmacy services designed to prevent hospitalizations and lower costs of care for older adults with heart failure and other chronic conditions; and
• NF2 Therapeutics (from en route to Montreal,  Michael Wootton, CEO), a biotechnology company developing gene replacement therapy to prevent deafness, loss of mobility and devastating brain tumors from NF2, and a targeted antibody-drug conjugate to treat meningiomas from NF2 and sporadic meningiomas. Both therapies are eligible for the FDA’s Orphan Drug Designation.

Members presented their due diligence report on Intraday, developing AI tools in the financial technology field to enable companies to forecast and deploy cash efficiently and more productive.

CEO Ron Murphy presented in person on the extension of Theromics’ fundraising round.

We heard updates on Beacon’s new portfolio companies:

• AmplifiDx, offering a Molecular Point-of-Care biotechnology platform via the DX 1000 System for accurate, convenient, and affordable infectious disease testing; and
• Hilltop BioSciences, a veterinary biotech company offering novel therapies for inflammatory diseases such as equine asthma and canine osteoarthritis.

November 9, 2021

Lightwater Biosciences & Shoreline Biome

At its monthly breakfast meeting on November 9, 2021, Beacon members met in person and remotely, where we heard new company funding proposals as follows:

• Lightwater Biosciences (speaking in person: CEO Soo-Young Kang & Bill McCullen of Launch Capital) offering biweekly subscriptions delivering freshly made, preservative- and irritant-free, perishable, short-use cycle, single-application, skincare products; and
• Shoreline Biome (speaking in person: Paul Denslow, CEO & CSO, Mark Driscoll) developing and selling patent-protected assays for human microbiome testing and research.

Beacon members presented due diligence reports on the following companies:

• Dermal Photonics, offering a patented device for home laser self-treatments superior to those of a professional dermatologist at a fraction of the cost;
• Embrace Prevention Care, which provides Personal Prevention Care, an integrated suite of geriatric telehealth and pharmacy services designed to prevent hospitalizations and lower costs of care for older adults with heart failure and other chronic conditions; and
• NF2 Therapeutics, developing gene replacement therapy to prevent deafness, loss of mobility and devastating brain tumors from NF2, and a targeted antibody-drug conjugate to treat meningiomas from NF2, with both therapies eligible for the FDA’s Orphan Drug Designation.

December 14, 2021

Jaia Robotics & Imago Rehab

In another hybrid meeting held on December 14, 2021, Beacon Angels members heard the following new company funding proposals:

• Jaia Robotics, developing “JaiaBots,” low-cost, high-speed, micro-sized autonomous aquatic robots that work in pods of up to 20 to collect aquatic data from coastal waters down to 100m, estuaries, rivers, lakes and marshlands; and
• Imago Rehab, providing a virtual clinic using telerehab supplemented by a robotic glove to facilitate daily, high-repetition rehabilitation by hand-impaired stroke patients. 

We heard updates on new and follow-on funding rounds as follows:

• Theromics‘ Series Seed extension round; and
• Dermal Photonics‘ convertible note with 20% warrant coverage.